Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...
Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease - ...
Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...
PROCESS Worldwide brings to you the ‘Top 10 plant engineering projects of October 2025’ from all over the world. Right from ...
Q3 2025 Earnings Call November 5, 2025 9:30 AM ESTCompany ParticipantsTroy Little - Chief Financial OfficerRichard Kruger ...
Objective To characterise and quantify the mortality risks for a range of causes after tropical cyclones in nine countries ...
In these uncertain, volatile, and unprecedented times, the role of science is more important than ever. Scientific advances that benefit humanity and ensure planetary sustainability for current and ...
Introduction Parkinson’s disease (PD) is a chronic neurodegenerative condition that affects approximately 10 million people worldwide. As the second most common neurodegenerative disease, its ...
Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback